NEW YORK (GenomeWeb) – Danaher reported on Thursday that its third quarter revenues rose 18 percent, year over year.

For the quarter ended Sept. 30, the company reported revenues of $4.13 billion, up from $3.51 billion in Q3 2015, and in line with the expectations of Wall Street analysts.

"Our team executed well despite the economic backdrop, and we were pleased with our performance in the third quarter as the strength and diversity of our portfolio continued to be a key differentiator," said President and CEO Thomas Joyce in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.